These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 17694310)

  • 1. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
    Prados MD; Yung WK; Wen PY; Junck L; Cloughesy T; Fink K; Chang S; Robins HI; Dancey J; Kuhn J
    Cancer Chemother Pharmacol; 2008 May; 61(6):1059-67. PubMed ID: 17694310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
    J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
    Loghin ME; Prados MD; Wen P; Junck L; Lieberman F; Fine H; Fink KL; Metha M; Kuhn J; Lamborn K; Chang SM; Cloughesy T; DeAngelis LM; Robins IH; Aldape KD; Yung WK
    Clin Cancer Res; 2007 Dec; 13(23):7133-8. PubMed ID: 18056194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
    Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
    Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
    Prados MD; Lamborn KR; Chang S; Burton E; Butowski N; Malec M; Kapadia A; Rabbitt J; Page MS; Fedoroff A; Xie D; Kelley SK
    Neuro Oncol; 2006 Jan; 8(1):67-78. PubMed ID: 16443950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh JJ; Gururangan S; Friedman AH; Desjardins A; Sathornsumetee S; Herndon JE; Dowell JM; McLendon RE; Provenzale JM; Sampson JH; Smith RP; Swaisland AJ; Ochs JS; Lyons P; Tourt-Uhlig S; Bigner DD; Friedman HS; Rich JN
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):860-8. PubMed ID: 16467100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
    Blakeley JO; Grossman SA; Mikkelsen T; Rosenfeld MR; Peereboom D; Nabors LB; Chi AS; Emmons G; Garcia Ribas I; Supko JG; Desideri S; Ye X
    J Neurooncol; 2015 Oct; 125(1):123-31. PubMed ID: 26285766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
    Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
    Mason WP; Macneil M; Kavan P; Easaw J; Macdonald D; Thiessen B; Urva S; Lwin Z; McIntosh L; Eisenhauer E
    Invest New Drugs; 2012 Dec; 30(6):2344-51. PubMed ID: 22160854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
    Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
    Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
    Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
    J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
    Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
    Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
    Lee EQ; Puduvalli VK; Reid JM; Kuhn JG; Lamborn KR; Cloughesy TF; Chang SM; Drappatz J; Yung WK; Gilbert MR; Robins HI; Lieberman FS; Lassman AB; McGovern RM; Xu J; Desideri S; Ye X; Ames MM; Espinoza-Delgado I; Prados MD; Wen PY
    Clin Cancer Res; 2012 Nov; 18(21):6032-9. PubMed ID: 22923449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
    Desjardins A; Reardon DA; Peters KB; Threatt S; Coan AD; Herndon JE; Friedman AH; Friedman HS; Vredenburgh JJ
    J Neurooncol; 2011 Dec; 105(3):601-6. PubMed ID: 21735117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
    Raizer JJ; Malkin MG; Kleber M; Abrey LE
    Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
    Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS
    Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.